Gufic BioSciences Limited has made available the audio recording of its earnings conference call held on August 17, 2026. The session commenced at 4:30 pm and is accessible via the company's official website.

The disclosure was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that a written transcript of the proceedings will be submitted at a later date.

Ami Shah, Company Secretary and Compliance Officer, signed the communication on behalf of the management.

Gufic Biosciences reported a strong start to FY27, with standalone net profit rising 23% year-on-year to ₹799.3 million for the quarter ended June 30, 2026. The growth was underpinned by a 15% increase in total income from operations, which logged ₹1,172.6 million, compared to ₹1,018.7 million in the corresponding period of the previous year.

On a consolidated basis, the company’s net profit after tax stood at ₹960.2 million, up from ₹781.4 million in Q1FY26. Consolidated revenue from operations grew 14% to ₹1,408.3 million, reflecting broad-based operational improvement across its business segments. The board of directors approved the unaudited financial results in a meeting held on August 14, 2026.

Financial Performance

The company’s profitability metrics showed consistent expansion both standalone and on a consolidated basis. Standalone profit before tax increased to ₹883.7 million from ₹717.8 million last year. On a consolidated level, profit before tax rose to ₹1,203.3 million from ₹983.9 million.

Earnings per share (basic) for the standalone entity were reported at ₹23.56, compared to ₹19.06 in the same quarter last year. Consolidated basic EPS stood at ₹35.78, an increase from ₹29.06 previously.

What the Numbers Show

The divergence between standalone and consolidated earnings highlights the significant contribution of subsidiaries to the group’s bottom line. While standalone revenue constituted approximately 83% of consolidated revenue, the standalone net profit accounted for only about 83% of the consolidated net profit, indicating efficient leverage or higher margins within certain consolidated entities. Furthermore, the consistent 23% growth rate in net profit across both standalone and consolidated structures suggests that the top-line revenue growth is translating directly into improved profitability without disproportionate cost inflation.

Regulatory Compliance

The financial results have been reviewed by the Audit Committee and approved by the Board of Directors. The statutory auditors have carried out a limited review of the results and expressed an unmodified audit opinion. The detailed format of the quarterly results is available on the websites of the stock exchanges and the company.